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ABSTRACT
Whole exome sequencing (WES) is increasingly used
in research and diagnostics. WES users expect cov-
erage of the entire coding region of known genes as
well as sufficient read depth for the covered regions.
It is, however, unknown which recent WES platform is
most suitable to meet these expectations. We present
insights into the performance of the most recent
standard exome enrichment platforms from Agilent,
NimbleGen and Illumina applied to six different DNA
samples by two sequencing vendors per platform.
Our results suggest that both Agilent and Nimble-
Gen overall perform better than Illumina and that
the high enrichment performance of Agilent is stable
among samples and between vendors, whereas Nim-
bleGen is only able to achieve vendor- and sample-
specific best exome coverage. Moreover, the recent
Agilent platform overall captures more coding exons
with sufficient read depth than NimbleGen and Illu-
mina. Due to considerable gaps in effective exome
coverage, however, the three platforms cannot cap-
ture all known coding exons alone or in combination,
requiring improvement. Our data emphasize the im-
portance of evaluation of updated platform versions
and suggest that enrichment-free whole genome se-
quencing can overcome the limitations of WES in suf-
ficiently covering coding exons, especially GC-rich
regions, and in characterizing structural variants.
INTRODUCTION
As a widely used method in genomic research and gene di-
agnostics, whole exome sequencing (WES) has the poten-
tial both to capture the entire coding region of all known
genes including flanking intronic regions and to provide se-
quence data from these enriched genomic regions with suffi-
cient read depth using a high-throughput DNA sequencing
technology (1–6). Without enrichment, whole genome se-
quencing (WGS) is more comprehensive and allows for the
characterization of the entire genome (7–10). As the human
exome represents only ∼2% of the human genome, but har-
bours ∼85% of all known disease-causing mutations, WES
is an increasingly used alternative to WGS (11–16).
Since performance comparisons of three major commer-
cial exome enrichment platforms from Agilent, NimbleGen
and Illumina were reported (2–6), new versions of these
platforms have been introduced. To date, however, it has
not been shown which new platform is superior in perfor-
mance and most suitable for diagnostic purposes. For this
reason and because our preliminary study (Supplementary
Figures S1 and S2) revealed that an updated version does
not necessarily lead to performance improvements, we as-
sessed themost recent version (v) of each platform (updated
end 2013).
Here, from the perspective of WES users, we present a
performance evaluation of exome captures from Agilent
(SureSelect v5+UTR), NimbleGen (SeqCap v3+UTR) and
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Illumina (Nextera Expanded Exome) applied to six human
DNA samples extracted from blood, saliva or cultured cells
and sequenced by different providers (vendors). One ven-
dor (V1) used all three platforms and applied the same data
analysis workflow (e.g. mapping, variant calling), ensuring
best comparability. In order to avoid vendor bias and to as-
sess the reproducibility of capture performance, each plat-
form was used by an additional vendor specialized in the
respective platform (V2, V3 and V4) as well, resulting in
two sets of WES data per platform for all six samples. This
study design allowed us to evaluate and compare the plat-
forms not only within the same experimental and bioinfor-
matics setting, similar to studies of previous platform ver-
sions (2–6), but also between different settings and among
different DNA sources, revealing hitherto unreported per-
formance differences, drawbacks and capabilities. Regard-
ing coverage of the entire coding exome, for two samples we
extended the performance evaluation of WES into the area
of WGS as well, including data of the most recent HiSeq X
Ten system.
MATERIALS AND METHODS
Preliminary study
Exomes of eight DNA samples (including all six samples
of this study, Table 1) were enriched using previous cap-
ture platforms from Agilent (SureSelect Human All Exon
kit v4+UTR) and NimbleGen (SeqCap EZ Human Ex-
ome v3) according to the manufacturer’s instructions. Sub-
sequently, prepared libraries were sequenced with 2 × 100
bp paired-end reads on a HiSeq 2000 sequencer (Illumina)
at the Functional Genomics Center Zurich, including data
analysis, which revealed distinct differences in the perfor-
mance of these previous enrichment platforms (Supplemen-
tary Figures S1 and S2).
Samples
DNA samples of six unrelated individuals, from which
informed consent was obtained, were selected for this
study. In each of these samples, Sanger sequencing and, if
available, multiplex ligation-dependent probe amplification
(MLPA) was previously performed for at least a subset of
genes listed in Supplementary Table S1 (17–20).
Genomic DNA was extracted from EDTA-
anticoagulated peripheral whole blood samples, saliva
and cells cultured from aortic walls or skin biopsies (fi-
broblasts) using either QIAamp DNA Mini kit (Qiagen)
or Chemagic Magnetic Separation Module I (Chemagen,
Perkin Elmer) according to the manufacturer’s instruc-
tions. Subsequently, some of the Chemagic extracted DNA
samples were purified using QIAampDNAMini kit as well
(Table 1). DNAs were quantified by OD measurements
(NanoDrop 2000, Thermo Scientific) and used for exome
enrichment according to the platform’s standard require-
ments, i.e. 3 g for Agilent, 1 g for NimbleGen and 50 ng
for Illumina.
Exome enrichment and high-throughput sequencing
Exome enrichment was performed using the most recent
versions (available by the end of 2013) of commercial se-
quence capture kits from Agilent (SureSelect Human All
Exon kit v5+UTR), NimbleGen (SeqCap EZ Exome (v3)
+UTR) and Illumina (Nextera Rapid Capture Expanded
Exome). The captured libraries were sequenced using a
HiSeq 2000/2500 sequencer (Illumina) and 2 × 100 bp
paired-end sequencing according to the manufacturers’ rec-
ommendations. As the size of the designed target regions
differs among platforms (Supplementary Table S2), the to-
tal expected read number was adjusted by the vendors to
obtain 100× coverage in all cases (i.e. sequencing at 100×
was requested for each sample). In addition to or instead
of this comparable coverage for each platform, the usage of
comparable number of reads was not pursued as this would
favour the platform with the smallest exome design (Illu-
mina).
Library preparation, sequence capture and high-
throughput sequencing was performed by four different
sequencing service providers (vendors V1–V4) according to
their standard workflow. One vendor (V1) sequenced all six
genomic DNA samples using all three exome enrichment
platforms, whereas the three other vendors sequenced the
six DNAs using only one platform in which they were
specialized (V2: Agilent; V3: NimbleGen; V4: Illumina;
Table 1). To extend our evaluation of the effect of DNA
sources, 24 additional DNA samples extracted from blood
(18 samples) or saliva (6 samples) were sequenced by V2 at
60× using Agilent capture (SureSelect v5) (Supplementary
Figure S3).
In addition to the three updated standard exome enrich-
ment platforms, the targeted (focused) enrichment of∼7600
clinically relevant genes was exemplified for sample 7739
and two additional DNA samples using the Accuracy and
Content Enhanced (ACE) clinical exome platform of Per-
sonalis with∼4gDNA sequenced at 60× on aHiSeq2500
system (ACEv2, www.personalis.com). Moreover, for two
out of the six DNA samples (7344 and 7739) WGS was
also performed by three vendors (V1, V3 and V4) using Il-
lumina’s TruSeq DNA PCR-Free Sample Preparation Kit
on a HiSeq 2000/2500 sequencer (Table 1). V1 performed
WGS at 60× coverage using 4 g DNA (sample 7739),
whereas V3 (samples 7344 and 7739) and V4 (sample 7739)
carried out sequencing at 30× using 2 and 4 g DNA, re-
spectively. Furthermore, for the DNA sample 7739 WGS
was also performed at 60× on a most recent HiSeq X Ten
sequencer (Illumina) by V4 using Illumina’s TruSeq Nano
DNA Sample Preparation Kit, which was not polymerase
chain reaction (PCR)-free but at the time of library prepa-
ration the only kit compatible with theHiSeqXTen system,
according to the manufacturer’s instructions for 350-bp in-
sert size.
Data analysis
Raw data processing, sequence read alignment from
FASTQ to BAM format and variant calling to generate
VCF files were performed by the four vendors (Supplemen-
tary Table S3). For our downstream analyses, aligned BAM
files with removed duplicated reads were used, which were
either directly provided by vendors (V3 and V4) or dedu-
plicated by us (V1 and V2) using Picard tools version 1.108
or 1.118 (http://picard.sourceforge.net). To determine the
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Table 1. Experimental design and characteristics of DNA samples used in this study
Sample # Gender DNA source Extraction method Purified WES/Vendora WGS/Vendor (coverage)
44 female blood Qiagen column no no WGS
280 female blood Chemagen no no WGS
326 female fibroblasts Chemagen no Agilent/V1, V2 no WGS
2905 male blood Chemagen yes NimbleGen/V1, V3 no WGS
7344 female blood Chemagen yes Illumina/V1, V4 HiSeq/V3 (30×)
7739 female saliva Chemagen yes HiSeq/V1 (60×), V3 (30×), V4
(30×) and XTen/V4 (60×)
Qiagen column, DNA extraction using Qiagen QIAamp DNAMini Kit; Chemagen, DNA extraction using PerkinElmer Chemagic Magnetic Separation
Module I; Purified, purification of the extracted DNA by re-extraction using Qiagen QIAamp DNAMini Kit; WES Agilent, SureSelect Human All Exon
kit v5+UTR; WES NimbleGen, SeqCap EZ Exome (v3) +UTR; WES Illumina, Nextera Rapid Capture Expanded Exome; V1–V4, vendors 1–4; WGS
HiSeq, TruSeq DNA PCR-Free Sample Preparation Kit on a HiSeq2000/2500 system; WGS XTen, TruSeq Nano DNA Sample Preparation Kit on a
HiSeq X Ten system.
aFor all six samples.
number of reads and the coverage at defined minimal read
depth (1, 10, 15 and 20×) of platform-specific target regions,
RefSeq exons and the subset of exons analysed by Sanger
sequencing and theACEplatformof Personalis, we used the
SeqMonk program version v0.25.0/v0.26.0/v0.27.0 (http:
//www.bioinformatics.babraham.ac.uk/projects/seqmonk)
with deduplicated BAM files and the settings ‘single-end
reads’ for data import to enable the counting of individual
reads and ‘remove exact duplicates’ for the option ‘feature
probe generator’ (Supplementary Tables S4–S15). Genomic
positions of target regions were downloaded from the plat-
forms’ websites, whereas genomic coordinates of RefSeq
exons were obtained from the UCSC Genome Browser
(http://genome.ucsc.edu/, version December 2013). The
GC content of RefSeq exons was calculated using the
Galaxy platform (http://usegalaxy.org). Data from the X
and Y chromosomes were included in our data analyses.
For arithmetic means, upper and lower confidence limits
(95% confidence intervals) were calculated using critical
values of paired t-test distribution (P = 0.05) and indicated
where appropriate.
In order to ensure the comparability of the platforms’
mutant (non-reference) allele enrichment performance, we
restricted our analyses of the provided VCF files (filtered, if
available, Supplementary Table S3) to shared sequence vari-
ants targeted by the design of each platform and located
in RefSeq coding exons completely covered at 20× by all
six platform-vendor combinations. The restriction to such
shared sequence variants should largely exclude possible
false-positive allele calls. Moreover, in order to avoid the in-
fluence of the vendors’ different data analysis workflows, we
generated genome VCF (gVCF) files, which store sequenc-
ing information for both variant and non-variant positions,
by applying the same in-house bioinformatics pipeline to all
six FASTQ files provided by V1–V4 for each DNA sample
(Supplementary Table S3). These gVCF files were filtered
to include only positions with ≥20 reads and >30 quality
scores in all samples and a non-reference allele (relative al-
lele proportion 10–90%) detected in at least one of the six
platform-vendor combinations within the platform’s target
region and 50-bp flanking sequences.
From our Sanger sequencing data, a total of 78 differ-
ent single nucleotide variants (SNVs) and 11 different in-
dels are known to be heterozygous in at least one of the six
DNA samples, including clinically relevant, disease-causing
mutations (Supplementary Tables S1 and S16). Thirty-five
variants (30 SNVs and 5 indels) are located within our re-
gion of interest (ROI) for clinical sequencing, which con-
sists of the entire protein-coding exonic regionwith−50 and
+20-bp flanking intronic sequences (Supplementary Figure
S4) and five SNVs affect UTR (Supplementary Table S1).
Using deduplicated BAM and unfiltered VCF files (Supple-
mentary Table S3), these variant positions were analysed for
read depth, calling and fraction of non-reference (alterna-
tive, mutant) allele and GC content of 30-bp flanking se-
quences (Supplementary Figures S5–S11 and Supplemen-
tary Tables S17–S20).
In addition, three samples (44, 7344 and 7739) were run
on a NimbleGen CGH/LOH 6 × 630K array (Roche) ac-
cording to the manufacturer’s instruction. This array con-
tains probes for a total of 501 common SNVs within Ref-
Seq coding exons. Array data of these SNVs located within
the designed target region of each platform and exons com-
pletely covered at 20× by all six platform-vendor combi-
nations (93, 101 and 53 SNVs for samples 44, 7344 and
7739, respectively) were compared to the corresponding
WES variant calls in the provided unfiltered and recali-
brated VCF files (Supplementary Table S3). In this compar-
ison, array positions with no array results or false-negative
or false-positive calls in all three platforms were excluded
(81, 93 and 39 array positions remained for the samples 44,
7344 and 7739, respectively).
The copy number variant (CNV) detection capability of
the platforms was assessed by comparing the relative read
depth of exons with known deletions (i.e. one copy) to the
read depth of normal flanking exons (i.e. two copies) in
affected samples and controls using Integrative Genomics
Viewer (IGV, Broad Institute). In addition, we also as-
sessed the detection of these deletions by applying theWES-
specific CNV calling tools cnMOPS (21) and XHMM (22)
for appropriate samples as well as the WGS-specific algo-
rithmBreakDancer (23) for corresponding chromosomes in
all four PCR-free WGS datasets. All three CNV detection
tools were used with default settings according to the devel-
opers’ instructions.Moreover, we calculated normalized rel-
ative base counts for RefSeq exons on autosomes according
toMLPAdata analysis (19). In details, the base counts of 21
769 exons completely (100%) covered at 20× in all 36 pro-
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vided WES BAM files (i.e. in all combinations of the three
platforms, sixDNA samples and two vendors) were used for
normalization. Copy number calculations were performed
for the samples 44, 280, 2905, 7344 and 7739 relative to the
sample 326, thereby only considering exons that in sample
326 achieved a coverage of 20× for at least one base and a
total base count of≥1000 in order to reduce the misleading
effect of incorrectly mapped reads. Using this calculation,
in order to further evaluate the CNV detection properties
of the three updated exome enrichment platforms, the rel-
ative base counts of 182 exons in 12 different genomic re-
gions with copy numbers known from a NimbleGen CGH
2.1M/4.2M array (Roche, Supplementary Table S21) were
assessed. In WGS, using the same 21 769 exons for normal-
ization as in WES, the reproducibility of copy number cal-
culation was assessed based on the base counts of sample
7739 and five additional DNA samples sequenced at 60×
on a HiSeq X Ten system as performed for sample 7739.
RESULTS
Platform design
In contrast to the designs (target regions) of previous plat-
form versions, NimbleGen now offers the largest target
region including coding and untranslated regions (UTR),
covering 96 Mb (64 Mb coding + 32 Mb UTR) compared
to 75 Mb (50 Mb coding + 25 Mb UTR) of Agilent and
62 Mb (42 Mb coding + 20 Mb UTR) of Illumina. More-
over, NimbleGen promises to capture the largest portion of
the entire RefSeq coding exome (98%) followed by Illumina
with 95% and Agilent with <94% (Table 2, Supplementary
Figure S12 and Supplementary Table S2). Almost each in-
dividual RefSeq exon is completely targeted by the designs
of NimbleGen (98%) and Illumina (94%) but, notably, in
nearly half of the cases (46%) only partially covered by the
design of Agilent (Supplementary Table S2).
Exome enrichment performance
Platform designs may let users expect certain WES perfor-
mances. However, the question is whether expectations de-
rived from platform designs meet the real laboratory per-
formances. In WES, captured DNA fragments sequenced
with sufficient quality result in reads which can be aligned
to the reference genome sequence (i.e. mapped), producing
an appropriate alignment (BAM) file per DNA sample. In
this study, for the six platform-vendor combinations, on av-
erage 55.2–90.4% of the raw reads remained after mapping
and deduplication, with duplicates accounting for 8.4–37%
of the mapped reads. Applying the same platform, the num-
ber of deduplicatedmapped readswas significantly different
between V1 and V2 (Agilent) as well as between V1 and V4
(Illumina). This difference is at least partially due to vari-
ation in the proportion of duplicated reads, suggesting the
impact of laboratoryworkflowonWES (Figure 1A, Supple-
mentary Figure S13 and Supplementary Tables S22–S24).
Indeed, duplicated readsmay rather depend on a laboratory
workflow, whereas variation in the proportion of unaligned
reads may rather be due to alignment tools as demonstrated
by comparing provided and in-house generated BAM files
(Supplementary Figure S13). Off-target enrichment was as-
sessed as the fraction of total aligned reads which mapped
more than 500 bp outside the designed target regions. As
in 2011 (3), Illumina showed the highest proportion of off-
target reads (∼40%) compared to Agilent and NimbleGen
(Figure 1A and Supplementary Tables S4 and S5).
While previous versions of NimbleGen showed the high-
est enrichment efficiency (2–5), the current version of Nim-
bleGen was only able to achieve best exome coverage in
some samples and vendor (Figures 1 and 2A). Similarly,
also Illumina showed distinct inter-sample and inter-vendor
variation. In contrast, for the Agilent platform the high en-
richment efficiency of target and coding regions was stable
between the two respective vendors and among all six DNA
samples (Figures 1 and 2, Supplementary Figure S14). The
latter result we confirmed by analysing 24 additional DNA
samples extracted from blood or saliva (Supplementary
Figure S3). This high enrichment performance and supe-
rior robustness of Agilent represents a clear improvement
of previous versions (Table 2 and Supplementary Figures
S1 and S2).
The comparison of the enrichment performances of the
three platforms used with the same experimental setting by
the same vendor (V1) revealed that Agilent reached the ex-
pected mean read depth of 100 (100×) for RefSeq coding
region (105 ± 17), 94.7 ± 1.2% of which were sequenced at
20×, i.e. with a read depth of at least 20 (Figure 1B and
Supplementary Table S6). NimbleGen with a mean read
depth of 93 ± 17 showed the lowest 20× coverage of Ref-
Seq coding region (79.0 ± 3.5%), whereas Illumina with
lowest mean read depth (79 ± 11) overall achieved signif-
icantly higher 20× RefSeq coverage (87.0 ± 2.3%). Similar
results for read depth and overall coverage performance was
revealed by V1 also for the platforms’ target regions (Fig-
ure 1A and Supplementary Table S4). The discrepancy be-
tween read depth and coverage performance observed for
NimbleGen and Illumina is most likely due to unequal read
distribution, which can be driven by the GC content of ge-
nomic sequences (24).
The uniformity of the coverage of RefSeq coding exons
was assessed by calculating the fraction of exons reaching
an average read depth within ±70% of mean read depth
over all coding exons (2).With the highest mean read depth,
Agilent reached a fraction of ∼80% regardless of vendor.
Similar results were obtained for Illumina (∼75%). In con-
trast, NimbleGen showed a high inter-vendor variation
with∼62% for V1 and∼93% for V3 (Figure 1B and Supple-
mentary Table S8), whereas WGS resulted in superior uni-
formity of the coverage of RefSeq coding exons with at least
97% (Supplementary Table S9).
In addition, we assessed what proportion of RefSeq cod-
ing exons are completely (i.e. 100%) covered at ≥20× and
hence suitable for clinical WES (5). Regardless of vendor,
Agilent performed best, however still far from 100%, with
an average of 86.7 ± 3.3% (V1) and 92.8 ± 1.0% (V2) fol-
lowed by NimbleGen with 72.4 ± 3.4% (V1) and 85.9 ±
14.1% (V3) as well as by Illumina with 63.1± 6.1% (V1) and
53.6± 4.2% (V4). Only 28.7± 5.8% of all RefSeq coding ex-
ons are completely covered at ≥20× by all three platforms
(Figure 3A and Supplementary Tables S8 and S10). In fact,
Agilent exceeded the expectation of complete (100%) exon
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Figure 1. Enrichment efficiency of the three updated exome enrichment platforms (Agilent, NimbleGen and Illumina) performed by four vendors (V1, V2,
V3 and V4). (A) Mean number of aligned reads (as million reads), mean read depth and percentage of coverage at 20× for each designed target region as
well as mean percentage of on-target reads (i.e. within designed target regions) and mean percentage of off-target reads (i.e. within regions more than±500
bp outside the designed target regions). Note that values for aligned reads indicate the total number of mapped reads without duplicates for V1 and V2
and only uniquely mapped reads without duplicates for V3 and V4 (Supplementary Table S3). (B) Mean read depth and percentage of coverage at 20× for
all and only coding exons of the RefSeq database as well as uniformity of the coverage of RefSeq coding exons calculated as the fraction of exons reaching
an average read depth within ±70% of mean read depth over all coding exons (uniformity coding). (C) Mean read depth and percentage of coverage at 15
and 20× for RefSeq coding exons as well as for −50-bp and +20-bp flanking intronic regions. Given are means of all six DNA samples (n = 6); error bars
indicate 95% confidence intervals. Values were calculated using the SeqMonk program (http://www.bioinformatics.babraham.ac.uk/projects/seqmonk/)
and are presented in Supplementary Tables S4-S8 and S12–S13. For complete coverage of RefSeq coding exons see Figure 3.
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Figure 2. Differences amongDNA samples. (A) Mean coverage of RefSeq exons (n= 233 644) at 20× (expressed in percentage of the entire exon length) for
all six platform-vendor combinations andDNA samples (44, 280, 326, 2905, 7344 and 7739) derived from blood, fibroblasts or saliva. Values were obtained
by using the SeqMonk program (www.bioinformatics.babraham.ac.uk/projects/seqmonk) and are presented in Supplementary Tables S6 and S12. Error
bars indicate 95% confidence intervals for the arithmetic means of all corresponding exons. (B and C) Mean coverage at ≥20 reads (B) and mean read
depth (C) of RefSeq exons per GC content for each DNA sample exemplified by the WES data of V2 using Agilent, demonstrating its high performance
stability across samples.
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Table 2. Overview of studies evaluating exome enrichment platforms as well as summary of which of the platforms performed best for the assessed aspects
This study Clark et al. 2011 (3) Asan et al. 2011 (2) Parla et al. 2011 (4) Sulonen et al. 2011 (5) Chilamakuri et al. 2014 (6)
Enrichment platforms Agilent v5+UTR,
NimbleGen v3+UTR
and Illumina Nextera
Expanded Exome
Agilent v3, NimbleGen
v2 and Illumina TruSeq
Exome
Agilent v1, NimbleGen
v1 (in-solution), 2.1M
array
Agilent v1 and
NimbleGen v1
Agilent v1, v3 and
NimbleGen v1, v2
Agilent v4, NimbleGen v3,
Illumina TruSeq Exome and
Illumina Nextera Expanded
Exome
Sequencing platform Illumina HiSeq
2000/2500 paired-end
100-bp reads
Illumina HiSeq 2000
paired-end 100-bp reads
Illumina HiSeq 2000
paired-end 90-bp reads
Illumina GAIIx,
paired-end 76-bp reads
Illumina GAIIx,
paired-end 82-bp reads
Illumina HiSeq 2000
paired-end 100-bp reads
DNA samples Six samples performed
by different vendors, 24
samples performed by
one vendor using
Agilent
One sample One sample Six HapMap samples
(two for both platforms
and four only for
NimbleGen)
One sample for all
platforms, 25 samples
for one platform
One sample with two
technical replicates per
platform
Region for sequence
variant calling
Common designed
target region in RefSeq
coding exons 100%
covered at 20× by all
platform-vendor
combinations
Genome-wide Designed target region
with 200-bp flanking
sequences
CCDS Genome-wide, designed
target region (individual
and common), and
CCDS
Designed target region
(individual and common),
CCDS, RefSeq (coding and
UTR) and Ensembl
Largest designed target
region
NimbleGen Illumina Agilent Agilent Agilent v2 NimbleGen
Largest coding region
(reference)
NimbleGen (RefSeq) Agilent (RefSeq,
Ensembl CDS)
Agilent (CCDS) Agilent (CCDS) Agilent v2 (CCDS) Illumina (CCDS, RefSeq,
Ensembl)
Best designed target
enrichment efficiency
Agilent NimbleGen NimbleGen (array and
in-solution)
NimbleGen NimbleGen v2 Agilent
Lowest off-target
enrichment
Agilent and NimbleGen NimbleGen NimbleGen (array and
in-solution)
NimbleGen NimbleGen v1 Agilent and NimbleGena
Best GC-rich region
enrichment
Agilent Agilent NimbleGen array No data NimbleGen v2 Illumina Nextera
Highest accuracy of
SNV detection
(benchmark)
Agilent (Sanger
sequencing, MLPA and
SNP array)
Agilent (SNP array) No clear difference
among platforms (SNP
array and WGS)
Agilent (HapMap and
1000 Genome Project
data)
NimbleGen v2 (SNP
array)
No determination of
accuracy by comparison to a
benchmark (only calling of
SNVs)
aEstimated from provided figures, as off-target reads were reported as relative proportion of filtered reads rather than total mapped reads; CCDS, Consensus Coding Sequences.
coverage from the capture design (cf. only 54.2% of the Ref-
Seq exons are covered 100% by the target design of Agi-
lent), whereas NimbleGen (98.3% expected) and Illumina
(94.0% expected) failed to reach their promised coverage
(Figure 3A and Supplementary Table S2). Our data suggest
that the proportion of incompletely covered exons can be
reduced by combining platform, rather than vendor, per-
formances. Indeed, the combination of the two best (Agi-
lent and NimbleGen) and all three platforms left only 2.3±
0.5% and 1.7± 0.3% of the RefSeq coding exons uncovered
at ≥20×, respectively, whereas the combined performance
of both vendors using Agilent (V1 and V2) could only re-
duce the proportion of not completely covered exons from
7.2 ± 1.1% (Agilent alone by V2) to 6.8 ± 0.9% (Figure
3B and Supplementary Table S10). Alternatively, particu-
larly focused enrichment can help to improve the standard
WES coverage of exons of interest as exemplified using a
clinical exome platform (Supplementary Table S11). How-
ever, in comparison to all exome enrichment platforms used
in this study, WGS (60×) showed fewer uncovered exons at
comparable read depth (i.e. at 10–15×; Supplementary Ta-
bles S9 and S11).
To assess the impact of GC content on enrichment per-
formance, we plotted mean read depth as well as mean
coverage at 20× against the GC content of RefSeq exons
(Figures 2B, C and 4 and Supplementary Figures S15 and
S16). Both Agilent and Illumina suggested correlation be-
tween GC content and read depth regardless of vendor,
whereas NimbleGen resulted in clear differences between
vendors and when performed by V3, also among samples.
Read depth of exons with very low (<20%) or high (>80%)
GC content was variable or low for all platforms, how-
ever, Agilent thereby performed more robust and slightly
better. This limitation of WES in capturing GC-rich re-
gions also differently affected previous platform versions
(Table 2) and can be overcome byWGS, as it is free from ge-
nomic hybridization/capture, especially by PCR-freeWGS.
Indeed, our PCR-free WGS data showed no distinct neg-
ative effect of high or low GC content on the mean read
depth of RefSeq exons, covering GC-rich regions (>80%)
much better thanWES.Non-PCR-freeWGS (HiSeqXTen)
achieved slightly lower enrichment ofGC-rich exons but the
observed bias was far less pronounced than in WES (Fig-
ure 5 and Supplementary Figure S17).
Enrichment and detection of non-reference alleles
Sequence variant detection by WES requires both the ex-
perimental enrichment and bioinformatics calling of mu-
tant alleles. As read alignment and variant calling can
considerably influence sequence variant detection (http://
genomeinabottle.org; http://www.bioplanet.com/gcat; 25),
we focussed on data generated by the same bioinformat-
ics workflow for the assessment of the enrichment of non-
reference (mutant) alleles. Accordingly, we focused on fil-
tered VCF files generated by the bioinformatics workflow
of V1 for all three platforms as well as gVCF files created
by our in-house data analysis pipeline for all six platform-
vendor combinations. We restricted the analysis of the pro-
vided VCF files to RefSeq coding regions, whereas we cre-
ated our gVCF files for the entire target region of each plat-
form including 50-bp flanking sequences. In both cases, for
each DNA sample only non-reference alleles covered and
called by all six platform-vendor combinations were consid-
ered in order to reduce the possibility of miscalling. In the
provided VCF files, by assessing the mean relative propor-
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Figure 3. Complete (i.e. 100%) coverage of RefSeq coding exons. (A) Proportion of RefSeq coding exons 100% covered by each designed target region
(design) and by ≥20 reads effectively produced by each vendor (vendors V1–V4). (B) Proportions of RefSeq coding exons not 100% covered at 20×
(missed exons). If not otherwise indicated, data of all corresponding vendors are included. Given are means of all six DNA samples (n = 6); error bars
indicate 95% confidence intervals. Values were calculated using the SeqMonk program (http://www.bioinformatics.babraham.ac.uk/projects/seqmonk/)
and are presented in Supplementary Tables S2, S8 and S10.
tion of non-reference alleles (26), no considerable difference
was observed among platforms neither for all variants nor
for indels only, suggesting comparable sensitivity to the de-
tection of mosaicism (Figure 6). Nevertheless, the enrich-
ment of non-reference alleles was more stable for Agilent,
resulting in reproducibly lower variation in the relative pro-
portions of alternative alleles compared to NimbleGen and
Illumina (Figure 6, Supplementary Figure S18 and Supple-
mentary Table S25). Moreover, as one might expect con-
sidering hybridization mismatches, the enrichment of non-
reference alleles was rather lower (<50%) than the capture
of reference ones (>50%). All these results derived from the
analysis of provided VCF files are supported by compara-
ble findings obtained from heterozygous SNVs character-
ized by Sanger sequencing (Supplementary Figure S10) as
well as from shared heterozygous SNVs and indels in our
in-house generated gVCF files (Supplementary Figures S19
and S20 and Supplementary Table S26).
To determine the accuracy of WES variant detection,
we analysed heterozygous SNVs and small indels, includ-
ing clinically relevant mutations, previously characterized
by Sanger sequencing in our DNA samples. Unlike previ-
ous studies (Table 2), we restricted this analysis to variants
in a ROI relevant for clinical sequencing, which comprises
exons with−50-bp and +20-bp flanking intronic sequences,
as well as to UTR variants. This Sanger-based benchmark-
ing provided not only themost accurate reference genotypes
(25) but also allowed us to compare WES with Sanger se-
quencing with respect to clinical use in our set of genes.
For all assessed heterozygous exonic positions, a minimum
read depth of 20 was achieved by all three updated plat-
forms. The coverage of intronic positions, however, varied
among platforms and DNA sources similar to the perfor-
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Figure 4. Differences in sensitivity to GC content among all platform-vendor combinations (average of all six DNA samples). (A and B) Scatter plot
showing GC content and achieved read depth of RefSeq exons (coding and UTR) for the three updated exome enrichment platforms performed by the
same vendor (V1, A) and different vendors (V2–V4, B), exemplified for sample 7344 (plots of all six samples are shown in Supplementary Figures S15
and S16). (C) Mean read depth of RefSeq exons per GC content shown as means of all samples. (D) Mean 20× coverage of RefSeq exons per GC content
shown as means of all samples.
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Figure 5. Influence of GC content on mean read depth in WGS. (A) GC content and achieved read depth of RefSeq exons (coding and UTR) exemplified
by WGS of sample 7344 performed by V3 (plots of all WGS datasets are shown in Supplementary Figure S17). (B) Means of read depths of RefSeq exons
per GC content. X Ten, HiSeq X Ten system.
mance observed genome-wide (Supplementary Figures S5
and S6). Regardless of vendor and hence also of mapping
and variant calling workflow, Agilent correctly detected all
our SNVs and called no false-positive variants, whereas
NimbleGen (V1) failed to detect one SNV in UTR and Illu-
mina (V4) identified three false-positive heterozygous SNVs
(Supplementary Tables S17–S19). By assessing calling accu-
racy for indels, which was not analysed in previous studies
(2–6), we found that all three platforms failed to detect some
small indels, although Agilent identified the highest num-
ber of indels in ROI (Supplementary Table S20). All anal-
ysed SNVs covered by array data (81, 93 and 39 for sam-
ples 44, 7344 and 7739, respectively) were called correctly
in WES regardless of platform and vendor (Supplementary
Table S27).
Moreover, our gVCF files generated by using the same
bioinformatics pipeline also allowed a comparative assess-
ment of variant detection in all six platforms-vendor com-
binations. We thereby focussed on positions with≥20 reads
and >30 quality scores which were called as heterozygous
by only one or by all but one platform and hence indicate
possibly false-positive or false-negative variant calls. Agi-
lent resulted in the lowest proportion of such putative call-
ing errors (0.82 ± 0.04% of all >14 000 analysed variant
positions) followed by NimbleGen (1.52 ± 0.10%) and Illu-
mina (1.66 ± 0.19%) (Supplementary Figure S21 and Sup-
plementary Table S28). However, high quality variants (≥20
reads and quality >30) called by all platforms may not be
sufficient to exclude all putative alignment errors and other
variant calling pipelines may also lead to different results.
Indeed, WES users should be aware that for the same raw
reads (FASTQ file) different read aligner and variant caller
combinations may result in considerably different number
of true and false variants (Genome Comparison & Analy-
sis Testing at http://www.bioplanet.com/gcat). The assess-
ment of the effect of bioinformatics pipelines on WES vari-
ant detection, however, is beyond the scope of this study and
should be addressed by further works focusing on this topic.
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Figure 6. Relative proportions of non-reference (mutant) alleles called in the VCF files provided by vendors (V1–V4). The analysis was restricted to shared
heterozygous variants within the designed target regions of the three platforms (Agilent, NimbleGen and Illumina) located in exons completely (100%)
covered at 20× by all six platform-vendor combinations. (A and B) Heterozygous SNVs (A) and indels (B) listed according to GC content of 30-bp flanking
sequences (for indel lengths see Supplementary Figure S18). Shown are values of all six DNA samples. Dashed lines indicate an interval within which 95%
of the relative proportions of non-reference alleles lie (calculated according to the Student’s t distribution as the mean of n percentage values ± critical
t-value (tcrit,n-1) × SD using n = 8 687, tcrit = 1.960 and n = 51, tcrit = 2.009 for A and B, respectively).
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The quantitative, CNV detection properties of the plat-
forms (27,28) were not evaluated in previous studies (2–6).
Thus, by using IGV we analysed one DNA sample (sample
44) that harbours a previously characterized heterozygous
27-kb deletion affecting the complete exon 1 of the FBN1
gene (19). Compared to the other five samples captured by
using Agilent and Illumina, the read depth of the deleted
exon 1 was distinctly lower than the read depth of the flank-
ing undeleted exons 2–5. For NimbleGen, however, the dis-
tribution of read depth among samples and exons was less
stable (regardless of alignment tool as confirmed by our
in-house generated BAM files) and thus the heterozygous
one-exon deletion was not clearly detectable (Supplemen-
tary Figure S22).Moreover, by using IGVwe analysedWES
and WGS data for a 7-kb deletion to compare their poten-
tial to detect large deletions (Supplementary Figure S23).
Both sequencing strategies allowed the detection of large
deletions by a reduction of read depth compared to flanking
exons and sequences, respectively. However, by using WGS
a more accurate determination of breakpoint positions is
possible, whereas by using WES additional methods may
be needed (29). Using CNV calling tools, none of the two
tested deletions were detected in the WES datasets by the
WES-specific cnMOPS (21) and XHMM (22) methods. In
contrast, the 7-kb deletion was called in all three PCR-free
WGS data sets (V1, V3 and V4) using the algorithm Break-
Dancer (23) (data not shown).
At genome-wide level, we extended the evaluation of the
CNV detection properties of the three updated exome en-
richment platforms not only for a large number of exons
and differentDNA samples but also formore knownCNVs.
The comparison of the relative base counts of 21 769RefSeq
exons completely covered at 20× in all 36 platform-vendor-
sample combinations showed the lowest variation for Ag-
ilent regardless of vendor and revealed comparable varia-
tion between WES and non-PCR-free WGS (Supplemen-
tary Figures S24 and S25 and Supplementary Table S29).
The lowest variation of Agilent and thus its potential for
best CNV detection was confirmed by assessing 182 exons
with copy numbers known from array CGH (Supplemen-
tary Figure S26 and Supplementary Table S30).
DISCUSSION
Users of WES expect coverage of the entire coding region
of all known genes and sufficient read depth for the covered
regions. This comparative study provides the most recent
and comprehensive data to answer the question of which
current standard WES enrichment platform is most suit-
able to meet these expectations. By including different se-
quencing providers (vendors) and samples into our perfor-
mance comparison, our study design allowed us to evaluate
the three most recent standard exome enrichment platforms
not only within the same experimental and bioinformatics
setting but also between different settings and among differ-
ent DNA sources. Our study focuses on the enrichment of
both reference and non-reference alleles, keeping the influ-
ence of bioinformatics workflow, which is a matter of ongo-
ing research, as low as possible. We observed that the Agi-
lent SureSelect HumanAll Exon v5+UTR enrichment plat-
form is superior to the other two platforms with regard to
overall performance and robustness. This superior perfor-
mance of the most recent Agilent platform is, however, not
applicable to its previous versions as shown by comparisons
in 2011 (Table 2) and our preliminary study (Supplementary
Figures S1 and S2).
Although the NimbleGen platform is designed to enrich
the largest target region and the highest proportion of the
coding region of the genome, the most recent version of the
Agilent platform produces higher and more consistent ex-
ome coverage. This discrepancy may at least partially be ex-
plained by different exome designs. Whereas the designed
target regions of NimbleGen and Illumina represent the re-
gion intended to be enriched, the target region specified by
Agilent only includes sequences effectively covered by hy-
bridization probes. Thus, the designed exome coverage does
not completely reflect effective hybridization probe cover-
age and exome enrichment efficiency (Figure 3A, Supple-
mentary Figures S4 and S12, and Supplementary Table S2).
This illustrates that information on the designed target re-
gion provided by platform selling companies may be mis-
leading for WES users, emphasizing the need for labora-
tory evaluation of real platform enrichment performances.
From a technical point of view, the performance of Agilent
may also, at least partially, be explained by the relatively
long RNA baits of this platform. It appears that longer
RNA baits lead to better hybridization and enrichment ef-
ficiency as well as tolerate larger hybridization mismatches
and thus provide more stable post-capture representation
of non-reference alleles harbouring sequence variants, espe-
cially indels (Figure 6, Supplementary Figures S10 and S18–
S20, and Supplementary Table S20). However, we observed
that the higher hybridization efficiency and mismatch toler-
ance of Agilent does not result in increased, unspecific off-
target capture (Figure 1A).
Alternatively,NimbleGenmay be the enrichmentmethod
of choice for users interested in regions exclusively covered
by this platform. However, users should be aware of more
pronounced bias for GC-rich regions and potentially re-
duced enrichment efficiency due to sensitivity to vendor and
DNA sources (Figures 1, 2 and 4). This bias and sensitivity
may be explained, at least partially if not all, by the relatively
low hybridization temperature during exome enrichment
(47◦C compared to 65◦C and 58◦C in Agilent and Illumina,
respectively) and/or by the relatively short size of hybridiza-
tion probes (55–105 bp DNA compared to 90/120 bp RNA
and 95 bp DNA in Agilent and Illumina, respectively; Sup-
plementary Table S2). For applications with limited start-
ing material, Illumina with 50 ng required DNA amount
is superior to NimbleGen and Agilent, both of which re-
quire more DNA as standard input (Supplementary Table
S2). For clinical WES, particularly focused exome enrich-
ment or the combination of Agilent and NimbleGen or of
all three platforms can result in 100% sequence coverage of
more exons than by using the standard platforms alone. As
the three platforms neither alone nor in combination can
completely capture all coding exons, the enrichment perfor-
mance of each platform requires improvement, at least for
exons of clinically relevant genes (Figure 3B, Supplemen-
tary Figure S27 and Supplementary Tables S9–S11).
Like Sanger sequencing, WES allows the simultaneous
analysis not only of coding exons but also of flanking in-
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tronic sequences involved in normal splicing as well as the
sufficient enrichment of non-reference alleles harbouring
SNVs and small indels, all of which are essential for the
detection of disease-causing mutations. Thus, the question
arises whether or notWES can replace Sanger sequencing in
mutation detection (30). Our data suggest that with respect
to RefSeq coding exons and flanking intronic sequences
none of the three updated WES platforms is suitable to re-
place Sanger sequencing, although Agilent appears to be
more suitable, not least due to its superior robustness (Fig-
ure 2). Hence, for best results, particularly in clinical WES,
the complete representation and sufficient coverage of each
tested gene region has to be ensured, especially for GC-rich
regions and deeper intronic positions.
Indeed, WES may fail to capture such regions and have
difficulties to detect CNVs. We observed that capture-free,
especially PCR-free, WGS can overcome these limitations,
making WGS superior to WES, at least in those cases. Fur-
thermore, the exome is not a fixed entity and still subject to
changes. Projects such as ENCODE (31) will enhance the
interpretation of non-coding, regulatory variants and their
importance in genomic research and gene diagnostics will
increase.With such changes in knowledge,WES capture de-
sign will require constant adaptation and for unsolved cases
a re-run of WES will have to be considered, whereas by us-
ing WGS the entire genomic information is largely present
so that only data analysis has to be repeated. One may as-
sume that WGS will become less expensive, as shown by the
recent introduction of the HiSeq X Ten system, and thus
be more popular in the near future. However, it remains
to be answered whether WGS will complement or replace
WES. It is probable that WES with less and better inter-
pretable sequencing data and emerging better enrichment
performance will be widely used as an effective alternative
to WGS in both research and diagnostics. Nevertheless, the
clinical application of these powerful tools should proceed
with care and be supported by the patient’s health insur-
ance, especially in testing a large number of exons and genes
as well as in cases in which no a priori knowledge of gene(s)
responsible for a particular disease phenotype exists.
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